- Home
- FUN vs IRON Comparison
FUN vs IRON Comparison
Compare FUN & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FUN
- IRON
- Stock Information
- Founded
- FUN 1983
- IRON 2017
- Country
- FUN United States
- IRON United States
- Employees
- FUN N/A
- IRON N/A
- Industry
- FUN Services-Misc. Amusement & Recreation
- IRON Biotechnology: Pharmaceutical Preparations
- Sector
- FUN Consumer Discretionary
- IRON Health Care
- Exchange
- FUN Nasdaq
- IRON Nasdaq
- Market Cap
- FUN 2.2B
- IRON 2.1B
- IPO Year
- FUN 1987
- IRON N/A
- Fundamental
- Price
- FUN $22.98
- IRON $86.22
- Analyst Decision
- FUN Buy
- IRON Strong Buy
- Analyst Count
- FUN 13
- IRON 12
- Target Price
- FUN $36.08
- IRON $105.42
- AVG Volume (30 Days)
- FUN 4.4M
- IRON 608.0K
- Earning Date
- FUN 11-07-2025
- IRON 11-07-2025
- Dividend Yield
- FUN 5.31%
- IRON N/A
- EPS Growth
- FUN N/A
- IRON N/A
- EPS
- FUN N/A
- IRON N/A
- Revenue
- FUN $3,168,142,000.00
- IRON N/A
- Revenue This Year
- FUN $17.13
- IRON N/A
- Revenue Next Year
- FUN $5.96
- IRON N/A
- P/E Ratio
- FUN N/A
- IRON N/A
- Revenue Growth
- FUN 67.95
- IRON N/A
- 52 Week Low
- FUN $20.00
- IRON $30.82
- 52 Week High
- FUN $49.77
- IRON $95.95
- Technical
- Relative Strength Index (RSI)
- FUN 48.23
- IRON 64.45
- Support Level
- FUN $24.03
- IRON $83.95
- Resistance Level
- FUN $27.37
- IRON $89.79
- Average True Range (ATR)
- FUN 1.57
- IRON 3.90
- MACD
- FUN 0.12
- IRON -0.05
- Stochastic Oscillator
- FUN 40.43
- IRON 60.22
About FUN Cedar Fair L.P.
Six Flags Entertainment Corp is North America's regional amusement resort operator with approximately 27 amusement parks, around 15 separately gated water parks, and nine resort properties across the U.S., Canada, and Mexico. It provides coasters, themed rides, thrilling water parks, resorts, and a portfolio of beloved intellectual properties such as Looney Tunes, DC Comics, and PEANUTS.
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.